2587:TSESuntory Beverage & Food Ltd. Analysis
Data as of 2026-07-31 - not real-time
HK$2.10
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Technical outlook: The price is trading below both the 20‑day and 50‑day simple moving averages, while the 200‑day average remains well above current levels, underscoring a bearish medium‑term trend. Momentum indicators show the RSI hovering in the lower‑mid range, suggesting limited upside momentum, yet the MACD histogram has turned marginally positive, hinting at a tentative short‑term bounce. Support and resistance are tight, with price flirting just above the identified support zone and below the nearest resistance, making the next few sessions pivotal. Volume dynamics are weakening, reinforcing the bearish bias as buying pressure wanes. Fundamental backdrop: Revenue has surged dramatically, outpacing the industry, but margins remain thin and the company carries modest debt. The price‑to‑earnings multiple sits slightly above the sector average, and a discounted cash‑flow model places intrinsic value below the market price, flagging potential overvaluation. Risk factors include pronounced 30‑day volatility, an historic max drawdown exceeding 80%, and elevated regulatory exposure inherent to Chinese healthcare services.
Given the confluence of a bearish technical framework, overvalued valuation metrics, and heightened regulatory and market volatility, the stock appears positioned for limited upside in the near term. Investors should monitor price action around the support level and any shifts in volume or MACD momentum before considering a position, while the strong revenue growth may warrant a longer‑term watch if valuation gaps narrow.
Given the confluence of a bearish technical framework, overvalued valuation metrics, and heightened regulatory and market volatility, the stock appears positioned for limited upside in the near term. Investors should monitor price action around the support level and any shifts in volume or MACD momentum before considering a position, while the strong revenue growth may warrant a longer‑term watch if valuation gaps narrow.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- price near immediate support with decreasing volume
- RSI in lower‑mid range indicating limited buying pressure
- MACD histogram marginally positive but overall trend bearish
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- robust revenue growth outpacing peers
- valuation above DCF fair value and sector PE
- persistent regulatory uncertainty in Chinese healthcare
Long Term
> 3 yearsNeutral
Model confidence: 5/10
Key Factors
- strong top‑line expansion and decent ROE
- high historical volatility and large max drawdown
- potential for valuation compression if market sentiment normalises
Key Metrics & Analysis
Financial Health
Revenue Growth77.30%
Profit Margin3.56%
P/E Ratio30.0
ROE21.12%
ROA5.67%
Debt/Equity14.56
P/B Ratio5.7
Op. Cash FlowHK$75.0M
Free Cash FlowHK$41.7M
Industry P/E29.2
Technical Analysis
TrendBearish
RSI36.2
SupportHK$2.01
ResistanceHK$2.52
MA 20HK$2.20
MA 50HK$2.71
MA 200HK$4.54
MACDBullish
VolumeDecreasing
Fear & Greed Index92.88
Valuation
Fair ValueHK$1.94
GradeOvervalued
TypeBlend
Risk Assessment
Beta0.31
Volatility61.23%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.